Friday, Aug 07, 2020 | Last Update : 06:03 PM IST

136th Day Of Lockdown

Maharashtra47977931637516792 Tamil Nadu2791442210874571 Andhra Pradesh1967891128701753 Karnataka158254802812897 Delhi1415311271244059 Uttar Pradesh108974634021918 West Bengal86754610231902 Telangana7525753239601 Gujarat65704485612529 Bihar6203140760349 Assam4816233429115 Rajasthan4667932832732 Haryana3779631226448 Odisha3768124483258 Madhya Pradesh3508225414912 Kerala279561629988 Jammu and Kashmir2239614856417 Punjab1901512491462 Jharkhand140705199129 Chhatisgarh10109761369 Uttarakhand8008484795 Goa7075511460 Tripura5520367528 Puducherry4147253758 Manipur301818147 Himachal Pradesh2879171013 Nagaland24056594 Arunachal Pradesh179011053 Chandigarh120671520 Meghalaya9173305 Sikkim7832971 Mizoram5022820
  Science   04 May 2020  Roche gets USFDA nod for coronavirus antibody test

Roche gets USFDA nod for coronavirus antibody test

REUTERS
Published : May 4, 2020, 12:34 pm IST
Updated : May 4, 2020, 12:34 pm IST

The brand claims its test relies on intravenous blood draws, which gives results with higher accuracy than finger-prick tests

 Representational Image. (AFP)
  Representational Image. (AFP)

Washington: Roche has won emergency approval from the U.S. Food and Drug Administration (FDA) for an antibody test to determine whether people have ever been infected with the coronavirus, the Swiss drugmaker on Sunday.

Thomas Schinecker, Roche’s head of diagnostics, said the company aims to more than double production of tests from about 50 million a month to significantly more than 100 million a month by the end of the year.

 

Governments, businesses and individuals are seeking such blood tests to learn who may have had the disease, who may have some immunity and to potentially craft strategies to help end national lockdowns.

Basel-based Roche, which also makes molecular tests to identify active COVID-19 infections, said its antibody test has a specificity rate exceeding 99.8% and sensitivity of 100%, meaning tests would show very few false positives and no false negatives.

A false-positive result could lead to the mistaken conclusion that someone has immunity. Roche said its test relies on intravenous blood draws, with higher accuracy than finger-prick tests.

 

“If you take blood from a finger prick, you will never be able to achieve the same level of specificity that you will achieve ... when you take blood from the vein,” Schinecker said.

“You have to have very, very high specificity. Even 0.1% or 0.2% makes a difference.”

RIVALS’ TESTS

Similar antibody tests have also been developed by companies including U.S.-based Abbott Laboratories, Becton Dickinson and Italy’s DiaSorin.

Abbott has said the specificity and sensitivity of its test are 99.5% and 100% respectively. Diasorin has said its Liason XL test has 97.4% sensitivity and 98.5% specificity.

As demand escalates for antibody tests, an array of distributors with no background or established testing competency have also joined the experienced companies in an all-but-unregulated marketplace in the United States, according to a Reuters investigation.

 

Roche did not disclose a price for its test but said that it would be identical worldwide.

Schinecker foresees a high need for testing healthcare workers and their families for exposure, and those who showed signs and symptoms, to see if they have antibodies.

While antibodies typically confer some immunity, Schinecker acknowledged that much remains to be learned about the novel coronavirus before drawing definitive conclusions.

“Since this virus is not well known, one can hypothesise, but the proof will take longer,” he said. “Testing these people ... is key to seeing whether or not people really have developed immunity.”

Tags: roche, coronavirus testing, covid-19, approval, thomas schinecker, abbott laboratories, becton dickinson, diasorin